At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 107 enrolled
Drug / intervention
esomeprazole 20 mgdrug
Likely dose
esomeprazole 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole
In Brief
A Phase 4 clinical trial evaluating esomeprazole 20 mg for Gastroesophageal Reflux Disease and 2 related conditions. Completed, enrolled 107 participants.
Detailed Summary
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease, GERD, Reflux Esophagitis
Countries--
CollaboratorsParexel
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartAug 2011
Primary CompletionJan 2012
TodayJul 2026
First PostedJul 19, 2011
Enrollment StartAug 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.0 years ago
Interventions
esomeprazole 20 mgdrug
esomeprazole 20 mg once daily for 8 weeks